. 2016 Dec;389(10087).
doi: 10.1016/S0140-6736(16)32417-5.

HER2-positive breast cancer

Sibylle Loibl 1 Luca Gianni 2 
  • PMID: 27939064
  •     95 citations


Anti-HER2 treatment for HER2-positive breast cancer has changed the natural biology of this disease. This Series article reviews the main achievements so far in the treatment of both metastatic and early HER2-positive breast cancer. The success of neoadjuvant therapy in HER2-positive early breast cancer is especially acknowledged, as pertuzumab has been approved on the basis of a higher proportion of patients achieving a pathological complete response with pertuzumab and trastuzumab than with trastuzumab alone in a neoadjuvant study. Event-free survival after the confirmatory adjuvant trial completed recruitment was numerically better with pertuzumab plus trastuzumab than with trastuzumab alone. With survival rates of almost 5 years in women with metastatic HER2-positive breast cancer and 75% of patients achieving a pathological complete response, new treatments in the past decade have clearly improved the prognosis of HER2-positive breast cancer. Despite these achievements, however, the persisting high toll of deaths resulting from HER2-positive breast cancer calls for continued, intensive clinical research of newer therapies and combinations.

Excellent Response with Ado-Trastuzumab Emtansine in a Patient with Relapsed Metastatic Breast Cancer Presenting with Pulmonary Lymphangitic Carcinomatosis.
Zhou Yu, Shobana Sankar, Marianne Huben.
Cureus, 2017 Sep 26; 9(7). PMID: 28944112    Free PMC article.
Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases.
Giulia Siravegna, Elena Geuna, +9 authors, Filippo Montemurro.
ESMO Open, 2017 Oct 27; 2(4). PMID: 29067216    Free PMC article.
Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells.
Sonja Thaler, Marcus Schmidt, +3 authors, Jonathan P Sleeman.
Oncotarget, 2017 Oct 27; 8(42). PMID: 29069787    Free PMC article.
HER2 expression patterns in paired primary and metastatic endometrial cancer lesions.
Mari Kyllesø Halle, Ingvild Løberg Tangen, +14 authors, Camilla Krakstad.
Br J Cancer, 2017 Nov 24; 118(3). PMID: 29169184    Free PMC article.
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.
Giuseppina Rosaria Rita Ricciardi, Alessandro Russo, +4 authors, Vincenzo Adamo.
BMC Cancer, 2018 Jan 27; 18(1). PMID: 29370839    Free PMC article.
Mitotically-Associated lncRNA (MANCR) Affects Genomic Stability and Cell Division in Aggressive Breast Cancer.
Kirsten M Tracy, Coralee E Tye, +5 authors, Jane B Lian.
Mol Cancer Res, 2018 Jan 31; 16(4). PMID: 29378907    Free PMC article.
Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?
Francesca Poggio, Matteo Lambertini, Evandro de Azambuja.
ESMO Open, 2018 Feb 02; 3(1). PMID: 29387483    Free PMC article.
Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes.
Christophe Alric, Katel Hervé-Aubert, +9 authors, Emilie Allard-Vannier.
J Nanobiotechnology, 2018 Feb 23; 16(1). PMID: 29466990    Free PMC article.
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Huiping Li, Jiang Liu, +15 authors, Erwei Song.
Nat Commun, 2018 Apr 25; 9(1). PMID: 29691399    Free PMC article.
Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells.
Marta Truffi, Miriam Colombo, +8 authors, Davide Prosperi.
Sci Rep, 2018 Apr 28; 8(1). PMID: 29700387    Free PMC article.
Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells.
Hans H Oberg, Christian Kellner, +6 authors, Daniela Wesch.
Front Immunol, 2018 May 05; 9. PMID: 29725336    Free PMC article.
Multi-drug therapy in breast cancer: are there any alternatives?
Partha Mitra.
Ann Transl Med, 2018 Jul 20; 6(11). PMID: 30023384    Free PMC article.
Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer.
Lorenzo Castagnoli, Egidio Iorio, +10 authors, Serenella M Pupa.
J Cell Physiol, 2018 Aug 23; 234(2). PMID: 30132876    Free PMC article.
Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs.
Nan Jiang, Jing-Jing Lin, +12 authors, Yan Cui.
Exp Ther Med, 2018 Sep 07; 16(3). PMID: 30186457    Free PMC article.
Breast Cancer Staging: Is TNM Ready to Evolve?
Fernando Cadiz, Juan G Gormaz, Mauricio Burotto.
J Glob Oncol, 2018 Sep 23; 4. PMID: 30241210    Free PMC article.
Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer.
Babak Nami, Hamid Maadi, Zhixiang Wang.
Cancers (Basel), 2018 Sep 23; 10(10). PMID: 30241301    Free PMC article.
Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics.
Karie Runcie, Daniel R Budman, Veena John, Nagashree Seetharamu.
Mol Med, 2018 Sep 27; 24(1). PMID: 30249178    Free PMC article.
Targeted Co-Delivery of Docetaxel and cMET siRNA for Treatment of Mucin1 Overexpressing Breast Cancer Cells.
Naime Majidi Zolbanin, Reza Jafari, +7 authors, Alireza Mohajjel Nayebi.
Adv Pharm Bull, 2018 Oct 03; 8(3). PMID: 30276134    Free PMC article.
Effects of Modulating Actin Dynamics on HER2 Cancer Cell Motility and Metastasis.
Sarah Nersesian, Rodette Williams, +5 authors, Andrew W Craig.
Sci Rep, 2018 Nov 24; 8(1). PMID: 30467396    Free PMC article.
Isolation and characterization of camelid single-domain antibodies against HER2.
Greg Hussack, Shalini Raphael, Michael J Lowden, Kevin A Henry.
BMC Res Notes, 2018 Dec 07; 11(1). PMID: 30518413    Free PMC article.
Staurosporine, an inhibitor of hormonally up-regulated neu-associated kinase.
Joelle N Zambrano, Christina J Williams, +7 authors, Elizabeth S Yeh.
Oncotarget, 2018 Dec 14; 9(89). PMID: 30542510    Free PMC article.
Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment.
Ada Koschorke, Simona Faraci, +13 authors, Serenella M Pupa.
Cell Oncol (Dordr), 2019 Aug 04; 42(6). PMID: 31376137
CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling.
Hee-Joo Choi, Sora Jin, +12 authors, Gu Kong.
EMBO Rep, 2019 Aug 31; 20(10). PMID: 31468695    Free PMC article.
Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab.
Xinle Wang, Lijing Cai, +5 authors, Yueping Liu.
Medicine (Baltimore), 2019 Sep 07; 98(36). PMID: 31490377    Free PMC article.
Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer.
Yan-Cui Liu, Ying Ma, +3 authors, Cheng Sun.
Medicine (Baltimore), 2019 Oct 01; 98(38). PMID: 31568001    Free PMC article.
Systematic Review.
Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007-2016).
Monica Tang, Andrea Schaffer, +4 authors, Sallie-Anne Pearson.
Br J Cancer, 2019 Nov 02; 121(11). PMID: 31673103    Free PMC article.
Subtype-Based Prognostic Analysis of Cell-in-Cell Structures in Early Breast Cancer.
Xin Zhang, Zubiao Niu, +10 authors, Qiang Sun.
Front Oncol, 2019 Nov 05; 9. PMID: 31681557    Free PMC article.
Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.
Ana Godoy-Ortiz, Alfonso Sanchez-Muñoz, +4 authors, Emilio Alba.
Front Oncol, 2019 Nov 19; 9. PMID: 31737566    Free PMC article.
Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors.
Holger Bronger, Viktor Magdolen, Peter Goettig, Tobias Dreyer.
Cancer Metastasis Rev, 2019 Sep 05; 38(3). PMID: 31482487    Free PMC article.
Monoclonal antibody-based molecular imaging strategies and theranostic opportunities.
Niels Dammes, Dan Peer.
Theranostics, 2020 Jan 07; 10(2). PMID: 31903161    Free PMC article.
Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials.
Amaia Eleonora Maennling, Mehmet Kemal Tur, +5 authors, Ahmad Fawzi Hussain.
Cancers (Basel), 2019 Nov 24; 11(12). PMID: 31756933    Free PMC article.
Gene Therapy for Liver Cancers: Current Status from Basic to Clinics.
Kenya Kamimura, Takeshi Yokoo, Hiroyuki Abe, Shuji Terai.
Cancers (Basel), 2019 Nov 27; 11(12). PMID: 31769427    Free PMC article.
Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast.
Yunjeong Jang, Hera Jung, +8 authors, Soo Youn Cho.
J Pathol Transl Med, 2019 Nov 14; 54(1). PMID: 31718120    Free PMC article.
Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer.
Lena-Christin Conradi, Melanie Spitzner, +10 authors, Marian Grade.
BMC Cancer, 2019 Sep 07; 19(1). PMID: 31488078    Free PMC article.
Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer.
Sandra Blasco-Benito, Estefanía Moreno, +20 authors, Cristina Sánchez.
Proc Natl Acad Sci U S A, 2019 Feb 09; 116(9). PMID: 30733293    Free PMC article.
Editorial Comment: 2017 Musculoskeletal Tumor Society Proceedings.
John H Healey.
Clin Orthop Relat Res, 2019 Feb 28; 477(4). PMID: 30811356    Free PMC article.
Cancer-associated fibroblasts: how do they contribute to metastasis?
Mei Qi Kwa, Kate M Herum, Cord Brakebusch.
Clin Exp Metastasis, 2019 Mar 09; 36(2). PMID: 30847799
The volumetric-tumour histogram-based analysis of intravoxel incoherent motion and non-Gaussian diffusion MRI: association with prognostic factors in HER2-positive breast cancer.
Chao You, Jianwei Li, +4 authors, Weijun Peng.
J Transl Med, 2019 Jul 03; 17(1). PMID: 31262334    Free PMC article.
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer.
Ami Hori, Masafumi Shimoda, +6 authors, Shinzaburo Noguchi.
Breast Cancer Res, 2019 Aug 08; 21(1). PMID: 31387614    Free PMC article.
Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer.
Qingfei Wang, Ian H Guldner, +4 authors, Siyuan Zhang.
Nat Commun, 2019 Aug 25; 10(1). PMID: 31444334    Free PMC article.
Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy.
Kei Ishii, Nao Morii, Hiroyasu Yamashiro.
Core Evid, 2019 Dec 06; 14. PMID: 31802990    Free PMC article.
Structure-Activity Relationship of HER2 Receptor Targeting Peptide and Its Derivatives in Targeted Tumor Therapy.
Beáta Biri-Kovács, Afrodité Adorján, +3 authors, Gábor Mező.
Biomolecules, 2020 Jan 30; 10(2). PMID: 31991749    Free PMC article.
MicroRNA-4417 is a tumor suppressor and prognostic biomarker for triple-negative breast cancer.
Chen Khuan Wong, Christopher Gromisch, +5 authors, Sam Thiagalingam.
Cancer biology & therapy, 2019 Mar 30; 20(8). PMID: 30922194    Free PMC article.
Correlation of HER2 codon 655 polymorphism with cardiotoxicity risk in Chinese HER2-positive breast cancer patients undergoing epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab adjuvant chemotherapy.
Lun Tan, Xinyu Su, +2 authors, Bo Hu.
Int J Clin Exp Pathol, 2020 Mar 27; 13(2). PMID: 32211111    Free PMC article.
DCST1-AS1 Promotes TGF-β-Induced Epithelial-Mesenchymal Transition and Enhances Chemoresistance in Triple-Negative Breast Cancer Cells via ANXA1.
Li Tang, Yuli Chen, +5 authors, Feng Yan.
Front Oncol, 2020 Apr 01; 10. PMID: 32226772    Free PMC article.
Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer.
Maria Gaibar, Laura Beltrán, +2 authors, Apolonia Novillo.
J Oncol, 2020 Apr 08; 2020. PMID: 32256585    Free PMC article.
Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models.
Regina Padmanabhan, Hadeel Shafeeq Kheraldine, +2 authors, Ala-Eddin Al Moustafa.
Cancers (Basel), 2020 Mar 14; 12(3). PMID: 32164163    Free PMC article.
Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.
Ugo Testa, Germana Castelli, Elvira Pelosi.
Med Sci (Basel), 2020 Mar 27; 8(1). PMID: 32210163    Free PMC article.
IGF-1 Interacted With Obesity in Prognosis Prediction in HER2-Positive Breast Cancer Patients.
Yiwei Tong, Jiayi Wu, +6 authors, Kunwei Shen.
Front Oncol, 2020 May 12; 10. PMID: 32391265    Free PMC article.
Evaluation of human epidermal growth factor receptor 2 status of breast cancer using preoperative multidetector computed tomography with deep learning and handcrafted radiomics features.
Xiaojun Yang, Lei Wu, +12 authors, Changhong Liang.
Chin J Cancer Res, 2020 May 16; 32(2). PMID: 32410795    Free PMC article.
Nomograms predicting survival for all four subtypes of breast cancer: a SEER-based population study.
Jianli Chu, Dehong Yang, Ling Wang, Jielai Xia.
Ann Transl Med, 2020 May 16; 8(8). PMID: 32411767    Free PMC article.
Therapeutic Effect of Trastuzumab in Neoadjuvant-Treated HER2-Positive Breast Cancer with Low Infiltrating Level of Tumor-Infiltrating Lymphocytes.
Shiwei Liu, Exian Mou, +8 authors, Jia Xu.
Cancer Manag Res, 2020 May 23; 12. PMID: 32440212    Free PMC article.
Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis.
Qitong Chen, Dengjie Ouyang, +35 authors, Quchang Ouyang.
Front Oncol, 2020 Jun 13; 10. PMID: 32528890    Free PMC article.
Acquired resistance to trastuzumab/pertuzumab or to T-DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728.
Hiroki Irie, Rumi Kawabata, +7 authors, Kenichi Matsuo.
Cancer Sci, 2020 Apr 06; 111(6). PMID: 32248641    Free PMC article.
The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T-DM1) in HER2-positive breast cancer cells.
Peipei Liu, Jiajun Fan, +4 authors, Dianwen Ju.
AMB Express, 2020 Jun 05; 10(1). PMID: 32495214    Free PMC article.
Metastatic Breast Cancer Coexisting With HER-2 Amplification and EGFR Exon 19 Deletion Benefits From EGFR-TKI Therapy: A Case Report.
Wei Jing, Jie-Tao Ma, Cheng-Bo Han.
Front Oncol, 2020 Jun 18; 10. PMID: 32547945    Free PMC article.
Actein Inhibits Tumor Growth and Metastasis in HER2-Positive Breast Tumor Bearing Mice via Suppressing AKT/mTOR and Ras/Raf/MAPK Signaling Pathways.
Xiao-Xiao Wu, Grace Gar-Lee Yue, +4 authors, Clara Bik-San Lau.
Front Oncol, 2020 Jun 18; 10. PMID: 32547952    Free PMC article.
Preliminary study on discriminating HER2 2+ amplification status of breast cancers based on texture features semi-automatically derived from pre-, post-contrast, and subtraction images of DCE-MRI.
Lirong Song, Hecheng Lu, Jiandong Yin.
PLoS One, 2020 Jun 20; 15(6). PMID: 32555662    Free PMC article.
Characterization of T-DM1-resistant breast cancer cells.
Juliette Sauveur, Louise Conilh, +4 authors, Charles Dumontet.
Pharmacol Res Perspect, 2020 Jun 26; 8(4). PMID: 32583565    Free PMC article.
Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients.
Jean Schneider, Hyouk Jin Lee, +6 authors, Hongki Gwak.
J Breast Cancer, 2020 Jul 01; 23(3). PMID: 32595988    Free PMC article.
Monitoring Value of Serum HER2 as a Predictive Biomarker in Patients with Metastatic Breast Cancer.
Pengyu Zhang, Jun Xiao, +2 authors, Xuejun Zhang.
Cancer Manag Res, 2020 Jul 02; 12. PMID: 32606958    Free PMC article.
Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems.
Maria Grazia Ferraro, Marialuisa Piccolo, +6 authors, Carlo Irace.
Cells, 2020 Jun 11; 9(6). PMID: 32517101    Free PMC article.
Specific Roles of HSP27 S15 Phosphorylation Augmenting the Nuclear Function of HER2 to Promote Trastuzumab Resistance.
Soo-Yeon Hwang, Seul-Ki Choi, +5 authors, Youngjoo Kwon.
Cancers (Basel), 2020 Jun 18; 12(6). PMID: 32545363    Free PMC article.
Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer.
Xiuwen Guan, Binliang Liu, +9 authors, Fei Ma.
Breast, 2020 Jan 14; 49. PMID: 31927339    Free PMC article.
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.
Kai Li, Ning Liao, +18 authors, Ning Liao.
Breast Cancer Res Treat, 2020 Jul 09; 183(2). PMID: 32638235    Free PMC article.
Patterns of Chest Wall Recurrence and Suggestions on the Clinical Target Volume of Breast Cancer: A Retrospective Analysis of 121 Postmastectomy Patients.
Lin-Wei Wang, Li Li, +2 authors, Ya-Hua Zhong.
Cancer Manag Res, 2020 Aug 09; 12. PMID: 32765092    Free PMC article.
A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM).
Anja Kathrin Wege, Nicole Kirchhammer, +6 authors, Gero Brockhoff.
J Transl Med, 2020 Aug 18; 18(1). PMID: 32799890    Free PMC article.
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy.
Jimin Yuan, Xiaoduo Dong, Jiajun Yap, Jiancheng Hu.
J Hematol Oncol, 2020 Aug 19; 13(1). PMID: 32807225    Free PMC article.
Past, Present, and Future of Anticancer Nanomedicine.
Kyungeun Kim, Dongwoo Khang.
Int J Nanomedicine, 2020 Aug 22; 15. PMID: 32821098    Free PMC article.
Iron(II) phthalocyanine Loaded and AS1411 Aptamer Targeting Nanoparticles: A Nanocomplex for Dual Modal Imaging and Photothermal Therapy of Breast Cancer.
Yubei He, Mengzhu Wang, +7 authors, Gengbiao Yuan.
Int J Nanomedicine, 2020 Aug 28; 15. PMID: 32848397    Free PMC article.
Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer From the US and Chinese Perspectives.
Qiuji Wu, Weiting Liao, +3 authors, Qiu Li.
Front Oncol, 2020 Aug 28; 10. PMID: 32850425    Free PMC article.
Combination of carbon-ion beam and dual tyrosine kinase inhibitor, lapatinib, effectively destroys HER2 positive breast cancer stem-like cells.
Sei Sai, Eun Ho Kim, +4 authors, Mitsuhiro Hayashi.
Am J Cancer Res, 2020 Sep 10; 10(8). PMID: 32905515    Free PMC article.
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry.
Michael P Lux, Naiba Nabieva, +28 authors, Sara Y Brucker.
Cancers (Basel), 2018 Dec 24; 11(1). PMID: 30577662    Free PMC article.
Efficacy and safety of targeted therapy for metastatic HER2-positive breast cancer in the first-line treatment: a Bayesian network meta-analysis.
Fubin Feng, Tingting Zhang, +8 authors, Changgang Sun.
Onco Targets Ther, 2019 Feb 19; 12. PMID: 30774382    Free PMC article.
LncRNAs GIHCG and SPINT1-AS1 Are Crucial Factors for Pan-Cancer Cells Sensitivity to Lapatinib.
Zhen Xiang, Shuzheng Song, +6 authors, Keqin Kathy Li.
Front Genet, 2019 Mar 08; 10. PMID: 30842786    Free PMC article.
The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation.
Babak Nami, Hamid Maadi, Zhixiang Wang.
Cancers (Basel), 2019 Mar 20; 11(3). PMID: 30884851    Free PMC article.
Comparative Efficacy and Tolerability of Neoadjuvant Immunotherapy Regimens for Patients with HER2-Positive Breast Cancer: A Network Meta-Analysis.
Di Wu, Tiejun Chen, +5 authors, Fenfang Wu.
J Oncol, 2019 Apr 25; 2019. PMID: 31015833    Free PMC article.
Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer.
Rasha M Sareyeldin, Ishita Gupta, +4 authors, Ala-Eddin Al Moustafa.
Cancers (Basel), 2019 May 15; 11(5). PMID: 31083383    Free PMC article.
Insulin-like growth factor-1, metabolic abnormalities, and pathological complete remission rate in HER2-positive breast cancer patients receiving neoadjuvant therapy.
Yi-Wei Tong, Gen Wang, +7 authors, Kun-Wei Shen.
Onco Targets Ther, 2019 Jun 14; 12. PMID: 31190894    Free PMC article.
The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?
Lorenzo Castagnoli, Michael Ladomery, Elda Tagliabue, Serenella M Pupa.
Cancers (Basel), 2019 Jul 03; 11(7). PMID: 31261614    Free PMC article.
Human Epidermal Growth Factor Receptor 2-positive Mucinous Carcinoma with Signet Ring Cell Differentiation, Which Showed Complete Response after Neoadjuvant Chemotherapy.
Yunjeong Jang, Eun Yoon Cho, Soo Youn Cho.
J Breast Cancer, 2019 Jul 10; 22(2). PMID: 31281734    Free PMC article.
Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis.
Hadar Goldvaser, Yasmin Korzets, +5 authors, Eitan Amir.
JNCI Cancer Spectr, 2019 Jul 31; 3(2). PMID: 31360906    Free PMC article.
Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma.
Bhavya Yarlagadda, Vaishnavi Kamatham, +2 authors, Pashtoon M Kasi.
NPJ Precis Oncol, 2019 Aug 28; 3. PMID: 31453370    Free PMC article.
Ivermectin, a potential anticancer drug derived from an antiparasitic drug.
Mingyang Tang, Xiaodong Hu, +6 authors, Qiang Fang.
Pharmacol Res, 2020 Sep 25;. PMID: 32971268    Free PMC article.
Depth of Response and Early Tumor Shrinkage for Predicting Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab.
Yi-Qun Che, Yue Zhang, +4 authors, Yang Luo.
Cancer Manag Res, 2020 Sep 29; 12. PMID: 32982445    Free PMC article.
Significant response to apatinib monotherapy in heavily pretreated advanced HER2-positive breast cancer: a case report and literature review.
Li Danni, Zhang Lingyun, +6 authors, Teng Yuee.
Cancer Biol Ther, 2020 Apr 03; 21(7). PMID: 32233990    Free PMC article.
Do we still need breast cancer screening in the era of targeted therapies and precision medicine?
Rubina Manuela Trimboli, Paolo Giorgi Rossi, +4 authors, Francesco Sardanelli.
Insights Imaging, 2020 Sep 26; 11(1). PMID: 32975658    Free PMC article.
Circulating miRNAs in HER2-Positive and Triple Negative Breast Cancers: Potential Biomarkers and Therapeutic Targets.
Ishita Gupta, Balsam Rizeq, +2 authors, Halema Al Farsi.
Int J Mol Sci, 2020 Sep 19; 21(18). PMID: 32942528    Free PMC article.
Expression and significance of Her2 and Ki-67 in gastric adenocarcinoma without distant metastasis: a cohort study.
Zhijian Wei, Lei Huang, Xinyue Zhang, Aman Xu.
BMC Gastroenterol, 2020 Oct 17; 20(1). PMID: 33059614    Free PMC article.
The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer.
Nathan Griffin, Mark Marsland, +5 authors, Sam Faulkner.
Biomolecules, 2020 Sep 23; 10(9). PMID: 32957504    Free PMC article.
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab.
Laura L Michel, Andreas D Hartkopf, +27 authors, Tanja N Fehm.
Cancers (Basel), 2020 Oct 22; 12(10). PMID: 33080911    Free PMC article.
Breast cancers, mammary stem cells, and cancer stem cells, characteristics, and hypotheses.
Sebastien Taurin, Haifa Alkhalifa.
Neoplasia, 2020 Nov 04; 22(12). PMID: 33142233    Free PMC article.
Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine.
Elena Laakmann, Julius Emons, +27 authors, Andreas D Hartkopf.
Geburtshilfe Frauenheilkd, 2020 Nov 12; 80(11). PMID: 33173241    Free PMC article.
Current Targets and Bioconjugation Strategies in Photodynamic Diagnosis and Therapy of Cancer.
Salvador Gomez, Allan Tsung, Zhiwei Hu.
Molecules, 2020 Oct 31; 25(21). PMID: 33121022    Free PMC article.
Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing.
Guan-Tian Lang, Yi-Zhou Jiang, +25 authors, Zhi-Ming Shao.
Nat Commun, 2020 Nov 12; 11(1). PMID: 33173047    Free PMC article.